Genetically modified tumor-targeted bacteria with reduced...

Details Genetically modified tumor-targeted bacteria with reduced... Genetically modified tumor-targeted bacteria with reduced...

2008-04-08

2008-04-08

Bui, Phuong T (Department: 1638)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Bacterium or component thereof or substance produced by said...

C424S258100, C424S093200, C424S093400, C435S252300, C435S252800, C435S879000

Reexamination Certificate

active

11064533

ABSTRACT:
The present invention is directed to mutantSalmonellasp. having a genetically modified msbB gene in which the mutantSalmonellais capable of targeting solid tumors. The invention is also directed toSalmonellasp. containing a genetically modified msbB gene as well as an genetic modification in a biosynthetic pathway gene such as the purl gene. The present invention further relates to the therapeutic use of the mutantSalmonellafor growth inhibition and/or reduction in volume of solid tumors.

REFERENCES:
patent: 4436727 (1984-03-01), Ribi
patent: 5021234 (1991-06-01), Ehrenfeld
patent: 5318900 (1994-06-01), Habuka et al.
patent: 5344762 (1994-09-01), Karapetian
patent: 5705151 (1998-01-01), Dow et al.
patent: 5824538 (1998-10-01), Branstrom et al.
patent: 5830702 (1998-11-01), Portnoy et al.
patent: 5877159 (1999-03-01), Powell et al.
patent: 5997881 (1999-12-01), Powell et al.
patent: 6051237 (2000-04-01), Paterson
patent: 6080849 (2000-06-01), Bermudes et al.
patent: 6150170 (2000-11-01), Powell et al.
patent: 6190657 (2001-02-01), Pawelek et al.
patent: 6251406 (2001-06-01), Haefliger et al.
patent: 6410012 (2002-06-01), Sizemore et al.
patent: 6447784 (2002-09-01), Bermudes et al.
patent: 6475482 (2002-11-01), Bermudes et al.
patent: 6537558 (2003-03-01), Kaniga
patent: 6605286 (2003-08-01), Steidler et al.
patent: 6685935 (2004-02-01), Pawelek et al.
patent: 6863894 (2005-03-01), Bermudes et al.
patent: 6923972 (2005-08-01), Bermudes et al.
patent: 6955953 (2005-10-01), Yamazaki et al.
patent: 6962696 (2005-11-01), Bermudes et al.
patent: 2001/0006642 (2001-07-01), Steidler et al.
patent: 2001/0029043 (2001-10-01), Haefliger et al.
patent: 2003/0059400 (2003-03-01), Szalay et al.
patent: 2004/0229338 (2004-11-01), King et al.
patent: 2005/0249706 (2005-11-01), Bermudes et al.
patent: 719446 (2000-08-01), None
patent: 749695 (2002-10-01), None
patent: 783714 (2006-03-01), None
patent: PI-9609016-2 (1996-06-01), None
patent: PI-9812079-4 (2000-03-01), None
patent: PI-0014491-6 (2002-04-01), None
patent: 2224075 (1997-12-01), None
patent: 2302866 (2000-03-01), None
patent: 2386465 (2002-04-01), None
patent: 00816714.1 (2000-08-01), None
patent: ZL96196140.6 (2004-02-01), None
patent: ZL98811030.X (2006-04-01), None
patent: 00195672 (1986-09-01), None
patent: 0285152 (1988-03-01), None
patent: 0322237 (1989-06-01), None
patent: 0338679 (1989-10-01), None
patent: 89302712.8 (1989-10-01), None
patent: 0357208 (1990-03-01), None
patent: 0400958 (1990-12-01), None
patent: 0564121 (1993-10-01), None
patent: 98 94 6891 (1998-09-01), None
patent: 1012232 (2000-06-01), None
patent: 1261369 (2002-12-01), None
patent: 0833660 (2006-12-01), None
patent: 03108220.2 (2003-11-01), None
patent: 1017253 (2004-07-01), None
patent: 1033956 (2006-11-01), None
patent: 134936 (2000-07-01), None
patent: 148933 (2002-03-01), None
patent: 62-145026 (1987-06-01), None
patent: 63-101328 (1988-05-01), None
patent: 01-180830 (1989-07-01), None
patent: 62-298657 (1994-10-01), None
patent: 2004-500042 (1997-12-01), None
patent: 2000-510842 (2000-03-01), None
patent: 2001-528552 (2002-04-01), None
patent: 2004-500042 (2002-04-01), None
patent: 3482213 (2003-10-01), None
patent: 70102535/2000 (2000-03-01), None
patent: 2002-7004371 (2002-04-01), None
patent: 0435932 (2004-06-01), None
patent: 979439 (1997-12-01), None
patent: 2000002355 (2000-03-01), None
patent: 2002/003384 (2002-04-01), None
patent: 312341 (1999-09-01), None
patent: 503376 (2003-02-01), None
patent: 518354 (2005-02-01), None
patent: 51176 (1998-12-01), None
patent: 200201817-4 (2002-04-01), None
patent: 71486 (2004-04-01), None
patent: WO 91/06317 (1991-05-01), None
patent: WO 92/11361 (1992-07-01), None
patent: WO/92/15689 (1992-09-01), None
patent: WO 95/02048 (1995-01-01), None
patent: WO/95/05832 (1995-03-01), None
patent: WO/1995/009655 (1995-04-01), None
patent: WO 96/11277 (1996-04-01), None
patent: WO 96/34631 (1996-11-01), None
patent: WO 96/40238 (1996-12-01), None
patent: WO/97/08955 (1997-03-01), None
patent: WO/97/18225 (1997-05-01), None
patent: WO 97/18837 (1997-05-01), None
patent: WO 97/19688 (1997-06-01), None
patent: WO 97/25061 (1997-07-01), None
patent: WO/98/53854 (1998-03-01), None
patent: WO 98/33923 (1998-08-01), None
patent: WO 99/13003 (1998-09-01), None
patent: WO/1998/053854 (1998-12-01), None
patent: WO 99/13053 (1999-03-01), None
patent: WO/99/13053 (1999-03-01), None
patent: WO/99/52563 (1999-10-01), None
patent: WO/00/09733 (2000-02-01), None
patent: WO/2001/025397 (2001-12-01), None
patent: WO/02/20809 (2002-03-01), None
patent: 98/8298 (1999-05-01), None
Adler, 1973, “A Method for Measuring Chemotaxis and Use of the Method to Determine Optimum Conditions for Chemotaxis byEscherichia coli,” J. Gen. Microbiol. 74:77-91.
Alizadeh, et al., 1994, “Apoptosis as a Mechanism of Cytolysis of Tumor Cells by a Pathogenic Free-Living Amoeba,” Infect. Immun. 62:1298-1303.
Anderson, W.F., 2001, “Recombinant DNA Advisory Committee Meeting, Jun. 14-15, 2001: Protocols Reviewed,” Human Gene Therapy 12:1593-1595.
Anderson, et al., 1996, “Development of attenuated Salmonella strains that express heterologous antigens,” Methods in Molecular Medicine: Vaccine protocols, ed. A. Robinson, G. Farrar, C. Wiblin, Humana Press, New Jersey, pp. 47-62.
Bagshawe, 1995, “Antibody-Directed Enzyme Prodrug Therapy: A Review,” Drug Rev. Res. 34:220-230.
Barry, et al., 1995, “Protection Against Mycoplasma Infection Using Expression-Library Immunization,” Nature 377:632-635.
Barth and Morton, 1995, “The Role of Adjuvant Therapy in Melanoma Management,” Cancer 75 (Suppl.):726-734.
Berggren, 1995, “Recombinant Salmonella as an Oral HIV Vaccine,” NIH Project No. 5 K08 AI01248-02.
Bone, 1993, “Gram-Negative Sepsis: A Dilemma of Modern Medicine,” Clin. Microbiol. Rev. 6:57-68.
Bonnekoh, et al., 1995, “Inhibition of Melanoma Growth by Adenoviral-Mediated HSV Thymidine Kinase Gene Transfer in vivo,” J. Invest. Derm. 104:313-317.
Carey, et al., “Clostridial Oncolysis in Man,” Eur. J. Cancer 3:37-46.
Carrier, et al., 1992, “Expression of Human IL-1beta inSalmonella typhimurium; a Model System for the Delivery of Recombinant Therapeutic Proteins in vivo,” J. Immunol. 148:1176-1181.
Carswell, et al., 1975, “An Endotoxin-Induced Serum Factor that Causes Necrosis of Tumors,” Proc. Natl. Acad. Sci. USA 72:3666-3670.
Chabalgoity, et al., 1996, “ASalmonella typhimuriumhtrA Live Vaccine Expressing Multiple Copies of a Peptide Comprising Amino Acids 6-23 of Herpes Simplex Virus Glycoprotein D as a Genetic Fusion to Tetanus Toxin Fragment C Protects Mice from Herpes Simplex Virus Infection,” Mol. Microbiol. 19:791-801.
Christ, et al., 1995, “E5531, a Pure Endotoxin Antagonist of High Potency,” Science 268:80-83.
Clements, 1995, “Attenuated Salmonella as Vaccine Vectors,” NIH Project No. 5 RO1 Al 28835-06.
Clementz, et al., 1997, “Function of theEscherichia colimsbB Gene, a Multicopy Suppressor of htrB Knockouts, in the Acylation of Lipid A,” J. Biol. Chem. 272(16):10353-10360.
Cunningham, et al., 1992, “Actin-Binding Protein Requirement for Cortical Stability and Efficient Locomotion,” Science 255:325-327.
Cunningham, C. and Nemunaitis, J., 2001, “Recombinant DNA Advisory Committee Meeting, Jun. 14-15, 2001: Protocols Reviewed,” Human Gene Therapy 12:1594-1596.
Curtiss, 1995, “Biological Containment of Live Bacterial Vaccines,” NIH Project No. 1 R41 Al38599-01.
Curtiss, 1994, “Avirulent Salmonella Host-Vector Vaccine Systems,” NIH Project No. 1 R41 Al36585-01.
Eisenstadt, 1987, “Analysis of Mutagenesis,” fromEscherichia coliandSalmonella tvphimurium, Cellular and Molecular Biology, Neidhardt, et al. (ed.), pp. 1016-1033.
Eisenstein, et al., 1995, “Immunotherapy of a Plasmacytoma with Attenuated Salmonella,” Med. Oncol. 12:103-108.
Engel, et al.,

Affiliated with

Also associated with

Rating

Genetically modified tumor-targeted bacteria with reduced... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Genetically modified tumor-targeted bacteria with reduced..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Genetically modified tumor-targeted bacteria with reduced... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3948490